MUMBAI, India and TEL AVIV, Israel, Sept. 6, 2024 /PRNewswire/ -- Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical ...
Compared with placebo, patients who received MM-II had clinically meaningful and sustained pain relief for up to 26 weeks. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
MUMBAI, India and TEL AVIV, Israel, April 24, 2025 /PRNewswire/ -- Sun Pharma (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) (Sun Pharmaceutical Industries Limited, and includes ...
Sun Pharma and Israel-based Moebius Medical Limited announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (large liposomes of DPPC and DMPC) for ...
Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company, has published clinical trial results for MM-II, a new non-opioid therapy developed for knee osteoarthritis pain relief. The ...
Sun Pharma and Israel-based Moebius Medical Limited announced the publication of two articles in osteoarthritis and cartilage, the official journal of the Osteoarthritis Research Society International ...
MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The two publications offer complementary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback